MedTrace Logo

Patients Who Receive 131 I-MIBG

NCT04770831 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2022-12-14

No results posted yet for this study

Summary

This study is for patients who have have neuroblastoma, pheochromocytoma, or paraganglioma that has come back (relapsed) after treatment or has not gotten better (refractory) with standard treatment. The purpose of this study is to evaluate quality of life and response rate to 131 I-MIBG treatment.

Conditions

  • Brain and Nervous System

Sponsors & Collaborators

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Javier Oesterheld, MD · Wake Forest University Health Sciences

Eligibility

Min Age
1 Year
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-10
Primary Completion
2024-12-31
Completion
2024-12-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04770831 on ClinicalTrials.gov